Welcome to our dedicated page for Science 37 Holdings news (Ticker: SNCE), a resource for investors and traders seeking the latest updates and insights on Science 37 Holdings stock.
Science 37 Holdings, Inc. (Nasdaq: SNCE) is a pioneering company based in Los Angeles that specializes in accelerating biomedical discovery through innovative, patient-centric clinical research models. Utilizing cutting-edge telemedicine technology, Science 37 offers a comprehensive range of services for conducting networked clinical trials, making it an invaluable partner for investigators, inventors, biotech firms, and large pharmaceutical companies.
At the core of Science 37's operations is the Metasite™, a proprietary virtual site platform that allows patients to participate in clinical trials from the comfort of their own homes or local healthcare providers. Powered by in-house medical and operational experts, the Metasite™ ensures uniform study orchestration, greater compliance, and high-quality data, thereby making clinical trials more accessible and efficient.
Science 37 leverages a vast network of partnerships with national mobile nursing companies, pharmacy chains, patient advocacy groups, and technology companies to streamline the clinical trial process. The company's recent achievements include the successful completion of a reverse stock split and a partnership with leading telemedicine companies, which has significantly expanded its reach and capabilities.
Noteworthy recent developments include the approval of a reverse stock split to comply with Nasdaq listing requirements and the commencement of a cash tender offer by eMed to purchase all outstanding shares of Science 37 at $5.75 per share. This move, coupled with the company's continuous efforts in enhancing patient recruitment through AI-powered screening and centralized processes, underscores its commitment to innovation and operational excellence.
Science 37 has also been recognized for its transformative impact on clinical research, winning the “Clinical Efficiency Innovation Award” at the 8th annual MedTech Breakthrough Awards. This award highlights the company's unique approach to patient recruitment, which has significantly improved patient randomization rates and site satisfaction.
For more detailed information and to stay updated on the latest developments, please visit Science 37's website.
Science 37 Holdings (Nasdaq: SNCE) announces a partnership with Linical Americas to enhance decentralized clinical trial solutions globally. The collaboration aims to improve patient access and support faster, more inclusive, and patient-centric trials, particularly in oncology, central nervous system, and infectious disease areas. This partnership leverages Science 37's innovative Metasite™ technology, aligning with both companies' missions to accelerate clinical research and reduce patient burden.
Science 37 Holdings, Inc. (NASDAQ: SNCE) reported financial results for the third quarter of 2022, highlighting a 14% revenue increase to $16.2 million compared to Q3 2021. However, net bookings dropped significantly to $4.7 million from $35.9 million the previous year due to contract signing delays. The company implemented a cost reduction program, cutting staff by 16% to save approximately $21 million annually. The revised 2022 revenue guidance is set at $68.2 million to $69.2 million, with an adjusted EBITDA outlook of $(65.4) million to $(66.4) million.
Science 37 Holdings, Inc. (Nasdaq: SNCE) will release its third quarter 2022 financial results on November 10, 2022, after market close. A conference call for investors is scheduled for November 11, 2022, at 8:30 a.m. ET. Interested participants must register in advance to obtain dial-in details. Following the call, a replay will be available for 90 days. Science 37 aims to enhance clinical research accessibility, utilizing a technology platform that enables faster enrollment and better retention in decentralized clinical trials.
Science 37 Holdings, Inc. (Nasdaq: SNCE) has appointed Paul von Autenried, former Chief Information Officer at Bristol Myers Squibb, to its Board of Directors. With over 26 years of leadership experience, von Autenried brings valuable industry and technology expertise to enhance Science 37's growth and its unique Agile Clinical Trial Operating System. He replaces Adam Goulburn, who contributed significantly to the company’s success, including its public offering in 2021. Science 37 aims to democratize clinical research through its innovative platform.
Science 37 Holdings, Inc. (Nasdaq: SNCE) has appointed Michael Shipton as Chief Commercial Officer to enhance business development and capitalize on the demand for decentralized clinical trials. With over 25 years of experience in clinical research, including significant sales achievements at Syneos Health, Shipton aims to drive enterprise growth and improve clinical trial accessibility. CEO David Coman emphasizes Shipton's expertise as critical for meeting ambitious growth goals. The company, known for its Agile Clinical Trial Operating System, seeks to streamline research processes for patients and providers.
Science 37 Holdings, Inc. (Nasdaq: SNCE) announced its participation in the Baird Global Healthcare Conference in New York, scheduled for September 13, 2022, at 3:45 p.m. Eastern Time. A live and archived webcast of the presentation will be available on the company's Investor Relations webpage.
Science 37 aims to improve access to clinical research through its Agile Clinical Trial Operating System™, enhancing the speed and diversity of patient enrollment while supporting decentralized clinical trials.
Science 37 Holdings, Inc. (Nasdaq: SNCE) has partnered with NuvoAir to enhance clinical trials by integrating remote respiratory endpoint data collection. This collaboration allows patients to participate in trials without needing to visit hospitals, significantly reducing patient burden. Utilizing a variety of connected devices and software, the solution aims to improve trial accessibility and diversity, achieving up to 21x faster patient enrollment and 28% better retention. With 3,781 active respiratory trials, the partnership is set to streamline trial processes and enhance patient experience.
Science 37 Holdings has introduced new patient relationship management and contact center technologies aimed at enhancing patient engagement for clinical trials. This initiative is expected to improve patient recruitment efficiency, leading to faster and more qualified enrollment. The new platform is designed to facilitate real-time communication between patients and study coordinators, addressing the challenges of traditional clinical trial participation. Importantly, Science 37 aims to eliminate geographic barriers, ultimately enhancing access to clinical research.
Science 37 Holdings (Nasdaq: SNCE) has partnered with Syapse to improve patient recruitment for oncology clinical trials through real-world data analytics. This collaboration aims to address the significant enrollment delays—often costing trial sponsors over $20 million monthly—by leveraging Syapse's patient identification capabilities and Science 37's agile trial systems. With over 3,700 active oncology trials globally and R&D spending projected at $70 billion in 2022, this partnership could enhance trial efficiency and accelerate access to new treatments for patients in need.
FAQ
What is the market cap of Science 37 Holdings (SNCE)?
What does Science 37 Holdings, Inc. specialize in?
What is the Metasite™?
What recent financial developments have occurred at Science 37?
What awards has Science 37 won recently?
How does Science 37 enhance patient recruitment for clinical trials?
Who are Science 37's main partners?
Where is Science 37 headquartered?
What is the aim of Science 37's clinical research models?
What is the significance of the reverse stock split for Science 37?
How can I learn more about Science 37's active studies?
